Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Raw Materials (2016 - 2025)

Heron Therapeutics' Raw Materials history spans 10 years, with the latest figure at $59.2 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 200.26% year-over-year to $59.2 million; the TTM value through Dec 2025 reached $59.2 million, up 200.26%, while the annual FY2025 figure was $59.2 million, 200.26% up from the prior year.
  • Raw Materials reached $59.2 million in Q4 2025 per HRTX's latest filing, up from $32.8 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $59.2 million in Q4 2025 to a low of $15.1 million in Q4 2022.
  • Average Raw Materials over 5 years is $22.9 million, with a median of $20.2 million recorded in 2021.
  • Peak YoY movement for Raw Materials: plummeted 36.02% in 2023, then skyrocketed 200.26% in 2025.
  • A 5-year view of Raw Materials shows it stood at $21.2 million in 2021, then decreased by 28.58% to $15.1 million in 2022, then grew by 16.56% to $17.6 million in 2023, then grew by 11.85% to $19.7 million in 2024, then surged by 200.26% to $59.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Raw Materials are $59.2 million (Q4 2025), $32.8 million (Q3 2025), and $35.8 million (Q2 2025).